Global Blood Therapeutics, Inc. (GBT) is a pioneering biopharmaceutical company headquartered in the United States, with a focus on developing innovative treatments for sickle cell disease and other blood disorders. Founded in 2011, GBT has made significant strides in the industry, particularly with its flagship product, Oxbryta (voxelotor), which uniquely targets the underlying cause of sickle cell disease by increasing haemoglobin's affinity for oxygen. With a commitment to transforming the lives of patients, GBT has established a strong market position, recognised for its dedication to research and development in the haematology sector. The company continues to expand its operational reach, aiming to address unmet medical needs and improve patient outcomes globally. Through its innovative approach and robust pipeline, Global Blood Therapeutics is at the forefront of advancing therapies that enhance the quality of life for individuals affected by blood disorders.
We don't have data for Global Blood Therapeutics, Inc., but we can show you information about their parent organization instead.
View parent company